

1 **Concentrations and immunostimulatory potential of circulating cell-free**
2 **membrane-bound and membrane-unbound mitochondrial DNA in preeclampsia**

3
4 Spencer C. Cushen^{1,2}, Contessa A. Ricci¹, Jessica L. Bradshaw¹, Talisa Silzer³,
5 Alexandra Blessing³, Jie Sun³, Sabrina M. Scroggins⁴, Mark K. Santillan⁴, Donna A.
6 Santillan⁴, Nicole R. Phillips³, Styliani Goulopoulou¹

7
8 ¹Department of Physiology and Anatomy, ²Texas College of Osteopathic Medicine,
9 ³Department of Microbiology, Immunology and Genetics, University of North Texas
10 Health Science Center, Fort Worth, Texas 76107, USA; ⁴Department of Obstetrics and
11 Gynecology, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242,
12 USA

13
14 Running Head: Cell-free circulating mtDNA in preeclampsia

15
16 Word count: Abstract: 257, Manuscript body: 3,542, References: 1,995, Figure legends:
17 497

18
19 Author for correspondence:

20 Styliani Goulopoulou, Ph.D., Department of Physiology and Anatomy, University of
21 North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX
22 76107, Email: styliani.goulopoulou@unthsc.edu, Phone: (817) 735-2973, Fax: (817)
23 735-5084

24 **ABSTRACT**

25 Cell-free circulating mitochondrial DNA (CFCmtDNA) is a damage-associated molecular
26 pattern (DAMP) that can activate Toll-like receptor 9 (TLR-9). The main objectives of
27 this case-control study were 1) to determine absolute concentrations and
28 immunostimulatory capacity of CFCmtDNA, in membrane-bound and -unbound states,
29 in cases with preeclampsia and healthy controls and 2) to implement a bootstrapped
30 penalized regression analysis to establish the contribution of CFCmtDNA to
31 preeclampsia diagnosis and its interaction with commonly collected patient
32 characteristics. To determine the contribution of membrane-bound and -unbound
33 CFCmtDNA in preeclampsia, DNA from plasma samples was extracted with lysis
34 buffer (membrane-unbound) and without lysis buffer (membrane-bound). CFCmtDNA,
35 quantified using absolute PCR quantification protocol, was reduced in preeclampsia
36 compared to healthy controls ($P \leq 0.02$). While the pattern of reduced CFCmtDNA in
37 preeclampsia was similar between methods of DNA extraction, DNA isolation with
38 membrane lysis buffer resulted in 1,000-fold higher CFCmtDNA quantification in the
39 preeclampsia group ($P = 0.0014$) and 430-fold higher CFCmtDNA quantification in the
40 control group ($P < 0.0001$). Even though CFCmtDNA concentrations were reduced,
41 plasma from women with preeclampsia induced greater TLR-9 activation than plasma
42 from gestational age matched controls ($P \leq 0.01$) as monitored using SEAP reporter 293
43 cells expressing human *TLR-9*. Penalized regression analysis showed that women with
44 preeclampsia are strongly likely to have high concentrations of nDNA and DNase I
45 along with a prior history of preeclampsia. Low concentrations of CFCmtDNA and mode
46 of delivery were also associated with preeclampsia. In conclusion, our data demonstrate

47 increases in the immunostimulatory potential of CFCmtDNA and upregulation of DNA

48 degradation mechanisms in women with preeclampsia at the third trimester.

49

50 **Keywords:** preeclampsia, mitochondrial DNA, cell-free DNA, DNase I, penalized

51 regression analysis

52 INTRODUCTION

53 Preeclampsia is a prevalent, multifactorial complication of pregnancy diagnosed as
54 de novo hypertension after the 20th week of gestation with end-organ damage¹. This
55 pregnancy-specific syndrome, which is seen in approximately 5-8% of pregnancies
56 worldwide, results in increased morbidity and mortality for fetus and mother alike.
57 Currently, there is no cure for preeclampsia and the most common approach to clinical
58 management is delivery of the fetoplacental unit², which often occurs preterm.

59 Often placentas from pregnancies with preeclampsia exhibit signs of damage in their
60 functional structures, the placental villi³, and exaggerated rates of trophoblast cell
61 death⁴. It has been proposed that placental damage results in release of anti-angiogenic
62 factors and pro-inflammatory cytokines along with cellular constituents and DNA
63 fragments, including mitochondrial DNA^{5, 6}, into the maternal circulation. Thus,
64 circulating factors are currently being studied as potential markers of early diagnosis
65 and placental health, and as predictors of pregnancy outcomes⁷⁻⁹.

66 Cell-free circulating mtDNA (CFCmtDNA) can act as a damage-associated
67 molecular pattern (DAMP) molecule, which elicits an immune response via activation of
68 the pattern recognition receptor, Toll-like receptor-9 (TLR-9)⁶. We and others have
69 previously reported that activation of TLR-9 during pregnancy induced preeclampsia-like
70 signs in rats and mice^{10, 11}. In line with these observations, TLR-9 activity was greater in
71 pregnant women with preeclampsia as compared to healthy pregnant women¹². Cross-
72 sectional and case-control studies have reported increased CFCmtDNA copy number in
73 serum and whole blood from women with preeclampsia in the third trimester^{13, 14} or at
74 time of delivery¹⁵. On the other hand, CFCmtDNA was suppressed in the first trimester

75 in women who later developed preeclampsia¹⁶. These previous studies suggest that
76 CFCmtDNA may be a potential pathogenic trigger or a contributor to the maintenance of
77 the maternal syndrome in preeclampsia.

78 The complex and multidimensional setting of preeclampsia poses many challenges
79 when elucidating the role of CFCmtDNA in the pathophysiology of preeclampsia. Before
80 determining whether CFCmtDNA is a trigger or a contributor to the maternal syndrome
81 of preeclampsia, it is imperative that we first address these challenges, providing
82 accurate and reliable quantifications. Thus, the main objectives of this case-control
83 study are to: a) overcome the current challenges of measuring CFCmtDNA, particularly
84 in limited sample sizes from pregnant women and b) determine the contribution of
85 CFCmtDNA to preeclampsia diagnosis and its interaction with commonly collected
86 patient characteristics.

87 One of the challenges of measuring CFCmtDNA is the accuracy of current protocols
88 in determining concentrations of CFCmtDNA in biological samples. Most methods utilize
89 relative PCR quantification approaches, which rely on a nuclear housekeeping gene.
90 However, we have found that concentrations of nuclear DNA (nDNA) increase with
91 advancing gestational age during pregnancy¹⁷, making quantification of CFCmtDNA
92 relative to nDNA liable to produce spurious results. In the present study, we overcome
93 this challenge by using our previously published absolute PCR quantification protocol
94 that does not rely on measurements of a housekeeping gene¹⁷. A second challenge is
95 that a significant part of mitochondrial genome is duplicated in the nuclear genome¹⁸
96 and therefore, it can be co-amplified by primers targeting CFCmtDNA. Here, we
97 address this limitation selecting for amplification a mitochondria-specific genomic region

98 that is absent from the nuclear genome^{19, 20}. A third challenge is the appropriate
99 implementation of multivariate statistical methods, which can be used to identify the
100 relationship between circulating factors, such as CFCmtDNA, with other variables in the
101 prediction of preeclampsia. Although logistic regression is often used when probing
102 factors underlying disease occurrence, small sample sizes lead to overfitting even in
103 balanced designs. To address this challenge, we employ bootstrapped penalized
104 regression analysis, a robust approach that produces reliable and generalizable
105 results^{21, 22}. This method allows us to evaluate the contribution of DNA metrics to
106 preeclampsia, in small sample sizes, while considering clinically significant covariates.

107

108 **METHODS**

109 Detailed methods are available in the on-line Data Supplement.

110

111 Subjects

112 De-identified subject information and blood samples were acquired from the Maternal
113 Fetal Tissue Bank (IRB# 200910784) of the Women's Health Tissue Repository at the
114 University of Iowa²³. Cases consisted of 19 pregnant women with preeclampsia and 19
115 healthy pregnant controls matched for gestational age (Table S1). As expected, the
116 preeclampsia group exhibited significantly higher mean, systolic, and diastolic blood
117 pressures and a significant lower gestational age of delivery, neonatal weight, and
118 APGAR scores ($P < 0.05$) in comparison to the control pregnancies. Maternal venous
119 blood was collected in the third trimester (mean = 33.6 weeks) and separated into

120 plasma and peripheral blood mononuclear cells (PBMCs) before storing at -80°C until
121 further processing.

122

123 DNA quantification

124 DNA was isolated and quantified as published previously¹⁷, with a few modifications.
125 Previous studies have noted that CFCmtDNA can be membrane-bound or -unbound²⁴,
126 ²⁵, suggesting vesicular and non-vesicular transport of CFCmtDNA within the circulation.
127 To determine the contribution of membrane-bound and -unbound CFCmtDNA in
128 preeclampsia, DNA from plasma samples was isolated with lysis buffer and without lysis
129 buffer. TaqMan™ chemistry-based absolute quantification of nDNA and CFCmtDNA
130 was used as detailed elsewhere¹⁷. Isolated CFCmtDNA was quantified using a method
131 modified from Kavlick et al.²⁰ and detailed previously¹⁷. The target sequence for this
132 analysis was the *MT-ND5* gene (mitochondrial NADH:ubiquinone oxidoreductase core
133 subunit 5; GenBank Gene ID: 4540), spanning positions 13,288-12,392 of the
134 mitochondrial genome²⁶. The qPCR primers, probes, and synthetic DNA standards used
135 for CFCmtDNA quantification are detailed in Table S2. Concentrations of plasma DNA
136 are expressed as picograms (pg) per mL of plasma. Total DNA was calculated as the
137 sum of CFCmtDNA and nDNA, in pg/mL plasma. Plasma CFCmtDNA is expressed in
138 absolute concentrations as a percent of total DNA (%CFCmtDNA). The DNA content of
139 PBMCs is presented as cell equivalent (Ceq) per microliter DNA isolate for nDNA and
140 as CFCmtDNA genome copies per cell equivalent.

141

142

143 Statistics

144 Normality tests, outlier removal and univariate analyses were performed using
145 Prism (Version 8, GraphPad, San Diego, CA, USA). Student's t-test and Mann-Whitney
146 *U* test were used for group comparisons. The effect of fetal sex on primary outcomes
147 was assessed with a two-way analysis of variance (ANOVA) followed by Sidak's post-
148 hoc analysis. DNA outcomes are presented in violin plots showing medians and ranges.
149 Subject characteristics are presented as mean with minimum and maximum unless
150 otherwise indicated. The significance level was set at $\alpha = 0.05$ for all comparisons.

151 To identify the most important subject characteristics associated with the
152 outcome of preeclampsia, bootstrapped penalized logistic regression was implemented.
153 All elements of regression analyses were carried out in R software version 4.0.2²⁷⁻³⁵.
154 Three penalized regression models (LASSO, ridge regression, elastic next regression)
155 were fit and their performances compared to select the best model. To adhere to test
156 assumptions of independent observations while not eliminating potentially important
157 patient characteristics, related characteristics were grouped *a priori* (Table S3), and an
158 in-house code was developed that selected a single characteristic from each group to
159 generate all possible combinations of independent characteristics ($n = 192$ datasets).
160 Bootstrapped ($R = 500$) 10-fold cross-validation LASSO, ridge, and elastic net were
161 then performed on each dataset and best model fit was assigned by lowest prediction
162 error. Predictive accuracy of the final model against a simulated naïve prediction
163 dataset was assessed by the bootstrap estimate ($R = 500$) of the area under the curve
164 of the receiver operator characteristic (AUC ROC) with confidence intervals (CI 95%)
165 calculated from standard error. Characteristics selected by the final regression model at

166 least 75% of the time (variable importance probability; VIP 0.75) for all bootstrap
167 samples were regarded as most important³⁶. Using this approach, the optimized
168 predictor combination and model were thus selected to best explain the association
169 between patient characteristics and the diagnosis of preeclampsia.

170

171 **RESULTS**

172 Concentrations of CFCmtDNA in lysis buffer-treated samples (Figure 1A) and in
173 samples that were not treated with lysis buffer (Figure 1B) were reduced in
174 preeclampsia compared to healthy controls. While the pattern of reduced CFCmtDNA in
175 preeclampsia remained the same between methods of DNA extraction, the exact
176 quantity of CFCmtDNA was reduced by 1000-fold in samples never treated with lysis
177 buffer (3.294 ± 0.828 vs. 0.003 ± 0.001 pg/mL, $n=15$, $P=0.0014$). In the control group,
178 concentrations of CFCmtDNA were reduced by 430-fold in samples never treated with
179 lysis buffer compared to samples treated with lysis buffer (9.011 ± 2.043 vs. $0.021 \pm$
180 0.004 pg/mL, $n=18$, $P<0.0001$). There were no group differences in plasma
181 concentrations of nDNA in samples treated with lysis buffer (Figure 1C), while plasma
182 concentrations of nDNA in samples treated without lysis buffer were increased in
183 women with preeclampsia compared to healthy controls (Figure 1D). Content of
184 CFCmtDNA and nDNA in PBMCs did not differ between groups (Figure 2A, B).

185 Plasma DNA concentrations were compared between pregnancies carrying male
186 and female fetuses. There was neither a main effect for sex nor a group-by-sex
187 interaction for plasma CFCmtDNA concentrations (Figure 3A); however, there was an

188 increase ($P=0.0003$) in circulating nDNA in pregnancies with preeclampsia carrying
189 female fetuses (Figure 3B).

190 Even though CFCmtDNA absolute concentrations were reduced, plasma from
191 women with preeclampsia induced greater TLR-9 activation than plasma from
192 gestational age-matched controls, regardless of whether TLR-9 activity was normalized
193 to lysis buffer extracted DNA ($P=0.01$, Figure 4A) or non-lysis buffer extracted DNA
194 ($P<0.0001$, Figure 4B).

195 Univariate analysis showed no differences ($P = 0.14$) in plasma DNase I
196 concentrations between control pregnancies and pregnancies with preeclampsia (Figure
197 5A). Moreover, there was no correlation ($P=0.5$) between DNase I concentrations and
198 CFCmtDNA in either group (Figure 5B). Plasma DNase I was not correlated to nDNA
199 ($P=0.2$) or %CFCmtDNA ($P=0.3$) in control pregnancies (Figure 5C, D). There were
200 moderate correlations ($P\leq 0.04$) between DNase I and nDNA and %CFCmtDNA in
201 preeclampsia (Figure 5C, D).

202 A total of 192 datasets (all possible combinations of independent observations
203 selected by in-house code in regression analysis) were analyzed to determine the best
204 combination of variables for modeling the relationships between patient history and
205 clinical characteristics, cell-free DNA, and the diagnosis of preeclampsia. The highest
206 performing combination of characteristics and corresponding coefficients and odds
207 ratios are listed in Table S4. After outlier removal via Mahalanobis distance, the final
208 dataset used in model building included $n=35$ patients (preeclampsia, $n=17$; control,
209 $n=18$). Assessing model performance between ridge, LASSO, and elastic net penalized
210 regression of the best performing dataset over $R=500$ bootstraps showed that elastic

211 net penalized regression produced the lowest prediction error (Table S5)^{37, 38}. This
212 model demonstrated an accuracy of approximately 100% (Table S6), and an AUC ROC
213 value of approximately 1 (Table S6, Figure S1).

214 Variable importance probabilities at 75% (VIP 0.75) indicated that 9 of the subject
215 characteristics considered were most important to the diagnosis of preeclampsia (Figure
216 6A). Characteristics with the largest effect (odds ratios) describing the diagnosis of
217 preeclampsia were higher levels of nDNA and DNase I and having a history of
218 preeclampsia (Figure 6B). Preeclampsia was also associated with lower levels of
219 membrane unbound CFCmtDNA, higher likelihood of having a cesarean section, higher
220 body mass index (BMI) at first obstetric visit, elevated mean arterial pressure and higher
221 maternal age.

222

223 **DISCUSSION**

224 The main findings of this study are a) absolute concentrations of plasma
225 CFCmtDNA are reduced in pregnant women with preeclampsia as compared to
226 gestational age-matched controls at the third trimester; b) preeclampsia diagnosis is
227 strongly associated with high circulating concentrations of nDNA, DNase I, and history
228 of preeclampsia, and moderately associated with lower levels of membrane-unbound
229 CFCmtDNA, higher maternal BMI, elevated mean arterial pressure, higher maternal
230 age, and higher likelihood of a cesarean section. Additionally, our findings showed that
231 the majority of CFCmtDNA within the maternal circulation is sequestered in vesicles
232 during late pregnancy and this phenomenon is more pronounced in preeclampsia.

233 Our study demonstrates reduced CFCmtDNA in plasma from women with
234 preeclampsia compared to controls. These quantities were determined in blood samples
235 collected at the third trimester but before labor and delivery. In contrast, Marschalek *et*
236 *al.* noted an increase in CFCmtDNA in serum of pregnant women (third trimester)
237 suffering from preeclampsia when compared to controls¹³. Methodological differences in
238 the protocol used to quantify CFCmtDNA may explain discrepancies between the
239 results of this study and those from previous investigations. In our study, we aimed to
240 address methodological limitations of previous research that might have introduced
241 bias. We specifically chose to amplify a mitochondrial genome region (position 13,288-
242 12,392) that has few known mutations and is absent from the nuclear genome. This
243 approach protects against the effects of hypervariability and pseudogene contamination,
244 respectively. To determine exact and not relative concentrations of CFCmtDNA, which
245 would rely on a nuclear housekeeping gene, we used a double-stranded, synthetic,
246 reference DNA. This method is highly sensitive for detecting minute quantities of
247 CFCmtDNA²⁰. Compared to these previous published protocols, these methodological
248 changes improve accuracy and help ensure unbiased results.

249 Extracellular CFCmtDNA can elicit a pro-inflammatory response driven by activation
250 of TLR-9^{6, 39, 40}. TLR-9 specifically recognizes hypomethylated cytidine-phosphate-
251 guanosine (CpG) motifs, which are common in bacterial DNA and mtDNA, but not in
252 nuclear DNA⁴¹. In the context of our study, none of the study participants had an
253 ongoing bacterial infection, and thus, we suggest that activation of TLR-9 was elicited
254 by mtDNA. Although concentrations of CFCmtDNA was reduced in our cohort of women
255 with preeclampsia, plasma from these subjects induced greater TLR-9 activity as

256 monitored using SEAP reporter 293 cells expressing the human *TLR-9* gene. This
257 finding is in agreement with previous studies showing increased TLR-9 activity in
258 women with preeclampsia at time of diagnosis¹². Our study extends these findings
259 demonstrating greater TLR-9 activity in the presence of lower concentrations of
260 CFCmtDNA in plasma from women with preeclampsia. This result suggests that
261 CFCmtDNA in plasma from women with preeclampsia has greater immunostimulatory
262 potency as compared to CFCmtDNA from normal pregnant women. Previous studies
263 have shown that CFCmtDNA modifications, such as oxidation, increase the
264 immunostimulatory potential of CFCmtDNA⁶. It is unknown whether CFCmtDNA of
265 women with preeclampsia undergoes modifications that alter their immunostimulatory
266 capacity.

267 While the pattern of reduced CFCmtDNA in preeclampsia was similar between
268 methods of DNA extraction, DNA isolation with membrane lysis buffer resulted in 1,000-
269 fold higher CFCmtDNA quantification in the preeclampsia group and 430-fold higher
270 CFCmtDNA quantification in the control group. Membrane-bound and -unbound nDNA
271 was also determined in these samples and although the membrane-unbound fraction
272 was greater than the membrane-bound nDNA, the magnitude of increase was much
273 smaller than what we observed for CFCmtDNA (Control: 27-fold increase,
274 Preeclampsia: 15-fold increase). Thus, most of the cell-free DNA, and particularly
275 CFCmtDNA, is membrane-bound in the maternal circulation in normal pregnancy and
276 more so in preeclampsia. These results are in agreement with previous studies
277 reporting that although circulating placenta-derived extracellular vesicles are present in
278 both normal pregnancy and in preeclampsia, the concentration of these vesicles is

279 greater in preeclampsia⁴². While mtDNA-containing extracellular vesicles have not been
280 identified in the context of preeclampsia, exosomes and mitochondria-derived vesicles
281 have been identified to contain CFCmtDNA⁴³. Greater cell-free, yet membrane-bound,
282 CFCmtDNA could be a component of several extracellular vesicles, including apoptotic
283 bodies⁴³, which may be related to changes in placental apoptosis in preeclampsia⁴⁴⁻⁴⁸.

284 In this study, we did not interrogate the source of CFCmtDNA. While it has been
285 demonstrated that circulating cell-free DNA is associated with placental size and
286 apoptosis of trophoblasts⁴⁹, it has yet to be shown whether the same relationship exists
287 between CFCmtDNA and placental dysfunction. Interestingly, placentas from
288 preeclamptic pregnancies are smaller and experience reduced perfusion⁵⁰⁻⁵⁴ and have
289 decreased villous surface area, suggesting that there is less area for maternal-fetal
290 communication, even when adequate perfusion is present⁵⁵⁻⁵⁸. Placental apoptosis is
291 increased⁴⁴⁻⁴⁸ and mitochondrial size, content, and bioenergetics are also altered in
292 preeclampsia^{44, 59-61}, and these changes may be secondary to placental hypoxia and
293 oxidative stress^{44, 59, 60}. Whether placental dysfunction in preeclampsia contributes to
294 CFCmtDNA and whether CFCmtDNA concentrations in the circulation reflect
295 mitochondrial health in the placenta warrants further investigation.

296 Previous studies have suggested that plasma CFCmtDNA and cellular mtDNA
297 copy number reflect different cellular processes in disease conditions. Intracellular
298 mtDNA copy number in PBMCs is thought to reflect variations in mitochondrial
299 bioenergetics and biogenesis⁶², while CFCmtDNA is mostly associated with cellular
300 stress and tissue damage⁶. Here, in addition to plasma CFCmtDNA concentrations, we
301 measured mtDNA copy number in PBMCs. In contrast to our findings in plasma

302 samples, we detected no group differences in PBMC mtDNA copy number, suggesting
303 dysregulation only occurred for extracellular mtDNA in this cohort of women with
304 preeclampsia.

305 Greater circulating nDNA, but not CFCmtDNA, was found in pregnant women
306 with preeclampsia who were carrying female fetuses than women carrying male fetuses.
307 This relationship was not observed in the control group. Female fetal sex is associated
308 with increased early preeclampsia and villous infarction⁶³, and male sex is associated
309 with term preeclampsia⁶⁴. In the context of preeclampsia, the placentas from female
310 offspring had greater villous infarction⁶⁵, while placentas from male offspring had greater
311 apoptosis and inflammation⁶⁶. Greater cell-free circulating nDNA in pregnancies
312 carrying female fetuses may reflect a sex-specific placental response in preeclampsia
313 that can be assessed in the maternal blood. It is noteworthy that our study was not
314 powered to determine the effects of fetal sex on cell-free DNA quantifications. Thus, we
315 should interpret these findings with caution.

316 We then examined the relationship between maternal and neonatal
317 characteristics and cell-free DNA by optimizing for the most informative subject data
318 and analyzing the magnitude of association and/or contribution to the diagnosis of
319 preeclampsia using elastic net penalized regression. Previously known relationships,
320 such as a higher likelihood of experiencing preeclampsia if a subject has a history of
321 preeclampsia^{67, 68}, and higher mean arterial blood pressure as part of the diagnostic
322 criteria¹, were corroborated by the elastic net regression model. Additionally, elastic net
323 regression mirrored univariate analyses showing lower levels of membrane-unbound
324 CFCmtDNA associated with preeclampsia. We also found that higher concentrations of

325 nDNA and DNase I are significant contributors to the diagnosis of preeclampsia. These
326 results contrast the outcome of DNase I in univariate tests. Although plasma
327 concentrations of DNase I were not significantly different in univariate tests, when
328 considered with patient medical histories, clinical data, and cell-free DNA metrics,
329 higher levels of DNase I may be representative of important processes that might
330 otherwise be missed by other analytical approaches. DNase I is a significant component
331 of cell-free DNA degradation and DNase I activity has been shown to be increased in
332 pregnant women with intrauterine growth restriction⁶⁹, a common feature of pregnancies
333 with preeclampsia. Collectively, we have demonstrated the utility of multivariate
334 analyses in capturing a more comprehensive understanding of available data, as
335 univariate testing may not reflect the importance that a variable possesses in a full
336 model. This computational approach allows us to identify phenotypic variables that may
337 contribute to preeclampsia.

338 Limitations of this study include a lack of diversity in subject race and ethnicity
339 and small sample sizes, which may limit the generalizability of our results. Nonetheless,
340 the demographics of the included subjects are representative of the Iowa population,
341 where the samples were collected. Further, DNA degradation mechanisms were not
342 studied extensively. Factors other than DNase I likely contribute to elimination of
343 circulating cell-free DNA, including filtration by the kidney or spleen, differential flux in
344 DNA release and uptake by tissues, and degradation by other DNA hydrolases⁷⁰.
345 Further assessment of placental function coupled with CFCmtDNA quantification could
346 shed insight on the origins of CFCmtDNA. Despite these limitations, our study provided
347 a novel, rigorous, and accurate measurement of exact concentrations of CFCmtDNA

348 and assessed the immunostimulatory potential of this CFCmtDNA in women with
349 preeclampsia. Finally, penalized regression analysis allowed for further interpretation of
350 clinical and molecular data, as it would have been easy to overlook the contribution of
351 DNase I concentrations when we found no difference in univariate analysis.

352 In conclusion, this study demonstrated that despite reductions in absolute
353 concentrations of CFCmtDNA in late pregnancy, plasma from women with preeclampsia
354 elicits greater TLR-9 activation compared to plasma from healthy pregnant women.
355 Through the use of penalized logistic regression, we have also identified greater DNase
356 I as a risk factor for preeclampsia.

357

358 **PERSPECTIVES**

359 This study provides a new approach for assessing the role of CFCmtDNA in
360 preeclampsia, implementing absolute quantification methods, amplifying a mitochondrial
361 genomic region that is absent from the nuclear genome, and utilizing a penalized
362 regression analysis to determine the contribution of circulating DNA and DNA
363 degradation mechanisms to preeclampsia. This computational analysis is particularly
364 robust for small sample sizes. Our data demonstrate increases in the
365 immunostimulatory potential of CFCmtDNA and upregulation of DNA degradation
366 mechanisms in women with preeclampsia during the third trimester. Additionally, this
367 study sets the foundation for future investigations in the exact role of CFCmtDNA in the
368 pathogenesis of preeclampsia, as previous studies have suggested that CFCmtDNA
369 may be a potential pathogenic trigger or a contributor to the maintenance of the
370 maternal syndrome in preeclampsia^{13, 15, 16}.

371 **ACKNOWLEDGMENTS**

372 Computational and Analytics resources were provided by the North Texas Scientific
373 Computing, a division under the of office of the Chief Information Officer for UNT and
374 UNT System. We would like to acknowledge Dr. Ravi Vadapalli and Dr. Richard
375 Herrington (North Texas Scientific Computing) for reviewing R scripts and consulting on
376 R code implementation.

377

378 **SOURCES OF FUNDING**

379 This research was supported in part by the American Heart Association
380 (19TPA34850131 (SG), 18PRE33960162 (SC), 18SCG34350001 (MKS), and
381 19IPLOI34760288 (MKS)), the National Institutes of Health (HL0146562 (SG), T32 AG
382 020494 (SC), UL1TR002537 (DAS, MKS), HD089940 (MKS), HD000849 (MKS),
383 RR024980 (MKS), and 3UL1TR002537 (MKS)), and Marche of Dimes (#4-FY18-851
384 (MKS)).

385

386 **DISCLOSURES**

387 No conflicts of interest, financial or otherwise, are declared by the author(s).

388 **FIGURE LEGENDS**

389 **Figure 1. Absolute qPCR of DNA in maternal plasma.** A) CFCmtDNA concentrations
390 (pg/mL) in plasma isolated using lysis buffer, B) CFCmtDNA concentrations (pg/mL) in
391 plasma isolated without lysis buffer, C) nDNA concentrations (pg/mL) in plasma isolated
392 using lysis buffer, and D) nDNA concentrations (pg/mL) in plasma isolated without lysis
393 buffer. A) and C) were analyzed using Student's t-test while B) and D) were analyzed
394 using Mann-Whitney *U* test. All values presented as median (white line) \pm IQR (black
395 lines). CFCmtDNA, cell-free circulating mitochondrial DNA; nDNA, nuclear DNA. Open
396 squares = gestational age matched control; open circles = third trimester pregnancies
397 with preeclampsia.

398

399 **Figure 2. Absolute qPCR of DNA isolated from maternal peripheral blood**
400 **mononuclear cells (PBMCs).** A) mtDNA copies per estimated number of PBMC and B)
401 nDNA concentration calculated as cell equivalents per microliter of PBMC DNA isolate.
402 Data analyzed using Student's t-test. All values presented as median (white line) \pm IQR
403 (black lines). nDNA, nuclear DNA; Ceq, cell equivalent. Open squares = gestational age
404 matched control; open circles = third trimester pregnancies with preeclampsia.

405

406 **Figure 3. Effect of fetal sex on plasma concentrations of DNA.** A) CFCmtDNA
407 concentrations (pg/mL) in plasma and B) nDNA concentrations (pg/mL) in plasma. Data
408 analyzed by two-way analysis of variance with Sidak's post-hoc analysis. All values
409 presented as median (white line) \pm IQR (black lines). nDNA, nuclear DNA; CFCmtDNA,
410 cell-free circulating mitochondrial DNA.

411 **Figure 4. TLR-9 activity of SEAP reporter 293 cells exposed to maternal plasma.**

412 A) TLR-9 activity of cells exposed to 10% maternal plasma normalized to CFCmtDNA
413 concentrations (pg/mL) in plasma when DNA was isolated using lysis buffer and B)
414 TLR-9 activity of cells exposed to 10% maternal plasma normalized to CFCmtDNA
415 concentrations (pg/mL) in plasma when DNA was isolated without lysis buffer. A) Mann-
416 Whitney *U* test. B) Student's t-test. All values presented as median (white line) \pm IQR
417 (black lines). TLR-9, toll-like receptor 9. Open squares = gestational age matched
418 control; open circles = third trimester pregnancies with preeclampsia.

419

420 **Figure 5. Plasma concentrations of DNase I measured in control pregnancies and**

421 **pregnancies with preeclampsia.** A) DNase I concentrations (ng/mL) in plasma, and
422 DNase I plotted as a concentration against B) CFCmtDNA concentration (pg/mL) in
423 plasma, C) nDNA concentration (pg/mL), and D) CFCmtDNA as a percent of total DNA.
424 A) Student's t-test, values presented as median (white line) \pm IQR (black lines). B-D)
425 Spearman correlation with *r* and *P* values presented for each analysis. CFCmtDNA and
426 nDNA used for Spearman correlations were derived from samples treated with lysis
427 buffer to extract DNA. nDNA, nuclear DNA; CFCmtDNA, mitochondrial DNA; totalDNA,
428 sum of CFCmtDNA & nDNA. Open squares = gestational age matched control; open
429 circles = third trimester pregnancies with preeclampsia.


430

431 **Figure 6. Subject characteristics most important to accurately determine**

432 **preeclampsia via elastic net penalized regression.** A) Subject characteristics whose
433 variable importance probabilities (VIP) reached at least 75%. B) Odds ratios of selected

- 434 subject characteristics. Vertical line represents OR = 1 (no effect); horizontal line
435 represents VIP 0.75 cutoff.


436 Figure 1



437


438

439 Figure 2




440

441 Figure 3




442

443 Figure 4




444

445 Figure 5



446

447 Figure 6



448

449 **REFERENCES**

- 450 1. American College of O, Gynecologists and Task Force on Hypertension in P.
451 Hypertension in pregnancy. Report of the American College of Obstetricians and
452 Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol.*
453 2013;122:1122-31.
- 454 2. American College of O and Gynecologists' Committee on Practice B-O.
455 Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.
456 *Obstet Gynecol.* 2020;135:e237-e260.
- 457 3. Falco ML, Sivanathan J, Laoreti A, Thilaganathan B and Khalil A. Placental
458 histopathology associated with pre-eclampsia: systematic review and meta-analysis.
459 *Ultrasound Obstet Gynecol.* 2017;50:295-301.
- 460 4. Travaglini A, Raffone A, Saccone G, Migliorini S, Maruotti GM, Esposito G,
461 Mollo A, Martinelli P, Zullo F and D'Armiento M. Placental morphology, apoptosis,
462 angiogenesis and epithelial mechanisms in early-onset preeclampsia. *Eur J Obstet*
463 *Gynecol Reprod Biol.* 2019;234:200-206.
- 464 5. Aucamp J, Bronkhorst AJ, Badenhorst CPS and Pretorius PJ. The diverse origins
465 of circulating cell-free DNA in the human body: a critical re-evaluation of the literature.
466 *Biol Rev Camb Philos Soc.* 2018;93:1649-1683.
- 467 6. West AP and Shadel GS. Mitochondrial DNA in innate immune responses and
468 inflammatory pathology. *Nat Rev Immunol.* 2017;17:363-375.
- 469 7. Rana S, Salahuddin S, Mueller A, Berg AH, Thadhani RI and Karumanchi SA.
470 Angiogenic biomarkers in triage and risk for preeclampsia with severe features.
471 *Pregnancy Hypertens.* 2018;13:100-106.

- 472 8. Gil MM, Galeva S, Jani J, Konstantinidou L, Akolekar R, Plana MN and
473 Nicolaides KH. Screening for trisomies by cfDNA testing of maternal blood in twin
474 pregnancy: update of The Fetal Medicine Foundation results and meta-analysis.
475 *Ultrasound Obstet Gynecol.* 2019;53:734-742.
- 476 9. Kwak DW, Kim SY, Kim HJ, Lim JH, Kim YH and Ryu HM. Maternal total cell-free
477 DNA in preeclampsia with and without intrauterine growth restriction. *Sci Rep.*
478 2020;10:11848.
- 479 10. Goulopoulou S, Wenceslau CF, McCarthy CG, Matsumoto T and Webb RC.
480 Exposure to stimulatory CpG oligonucleotides during gestation induces maternal
481 hypertension and excess vasoconstriction in pregnant rats. *Am J Physiol Heart Circ*
482 *Physiol.* 2016;310:H1015-25.
- 483 11. He B, Yang X, Li Y, Huang D, Xu X, Yang W, Dai Y, Zhang H, Chen Z and
484 Cheng W. TLR9 (Toll-Like Receptor 9) Agonist Suppresses Angiogenesis by
485 Differentially Regulating VEGFA (Vascular Endothelial Growth Factor A) and sFLT1
486 (Soluble Vascular Endothelial Growth Factor Receptor 1) in Preeclampsia.
487 *Hypertension.* 2018;71:671-680.
- 488 12. Williamson RD, McCarthy FP, Kenny LC and McCarthy CM. Activation of a TLR9
489 mediated innate immune response in preeclampsia. *Sci Rep.* 2019;9:5920.
- 490 13. Marschalek J, Wohlrab P, Ott J, Wojta J, Speidl W, Klein KU, Kiss H, Pateisky P,
491 Zeisler H and Kuessel L. Maternal serum mitochondrial DNA (mtDNA) levels are
492 elevated in preeclampsia - A matched case-control study. *Pregnancy Hypertens.*
493 2018;14:195-199.

- 494 14. McCarthy C and Kenny LC. Therapeutically targeting mitochondrial redox
495 signalling alleviates endothelial dysfunction in preeclampsia. *Sci Rep.* 2016;6:32683.
- 496 15. Qiu C, Hevner K, Enquobahrie DA and Williams MA. A case-control study of
497 maternal blood mitochondrial DNA copy number and preeclampsia risk. *Int J Mol*
498 *Epidemiol Genet.* 2012;3:237-44.
- 499 16. Busnelli A, Lattuada D, Ferrari S, Reschini M, Colciaghi B, Somigliana E, Fedele
500 L and Ferrazzi E. Mitochondrial DNA Copy Number in Peripheral Blood in the First
501 Trimester of Pregnancy and Different Preeclampsia Clinical Phenotypes Development:
502 A Pilot Study. *Reprod Sci.* 2018:1933719118804410.
- 503 17. Cushen SC, Sprouse ML, Blessing A, Sun J, Jarvis SS, Okada Y, Fu Q, Romero
504 SA, Phillips NR and Goulopoulou S. Cell-free mitochondrial DNA increases in maternal
505 circulation during healthy pregnancy: a prospective, longitudinal study. *Am J Physiol*
506 *Regul Integr Comp Physiol.* 2020;318:R445-R452.
- 507 18. Wang X, Weidling I, Koppel S, Menta B, Perez Ortiz J, Kalani A, Wilkins HM and
508 Swerdlow RH. Detection of mitochondria-pertinent components in exosomes.
509 *Mitochondrion.* 2020;55:100-110.
- 510 19. Kavlick MF. Development of a triplex mtDNA qPCR assay to assess
511 quantification, degradation, inhibition, and amplification target copy numbers.
512 *Mitochondrion.* 2019;46:41-50.
- 513 20. Kavlick MF, Lawrence HS, Merritt RT, Fisher C, Isenberg A, Robertson JM and
514 Budowle B. Quantification of human mitochondrial DNA using synthesized DNA
515 standards. *J Forensic Sci.* 2011;56:1457-63.

- 516 21. Makalic E and Schmidt DF. Review of Modern Logistic Regression Methods with
517 Application to Small and Medium Sample Size Problems. 2011:213-222.
- 518 22. Liao JG and Chin K-V. Logistic regression for disease classification using
519 microarray data: model selection in a large p and small n case. *Bioinformatics*.
520 2007;23:1945-1951.
- 521 23. Santillan MK, Leslie KK, Hamilton WS, Boese BJ, Ahuja M, Hunter SK and
522 Santillan DA. Collection of a lifetime: a practical approach to developing a longitudinal
523 collection of women's healthcare biological samples. *Eur J Obstet Gynecol Reprod Biol*.
524 2014;179:94-9.
- 525 24. Keseru JS, Soltesz B, Lukacs J, Marton E, Szilagyi-Bonizs M, Penyige A, Poka R
526 and Nagy B. Detection of cell-free, exosomal and whole blood mitochondrial DNA copy
527 number in plasma or whole blood of patients with serous epithelial ovarian cancer. *J*
528 *Biotechnol*. 2019;298:76-81.
- 529 25. Ye W, Tang X, Liu C, Wen C, Li W and Lyu J. Accurate quantitation of circulating
530 cell-free mitochondrial DNA in plasma by droplet digital PCR. *Anal Bioanal Chem*.
531 2017;409:2727-2735.
- 532 26. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J,
533 Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R and
534 Young IG. Sequence and organization of the human mitochondrial genome. *Nature*.
535 1981;290:457-65.
- 536 27. R: A language and environment for statistical computing. [computer program].
537 Vienna, Austria: R Foundation for Statistical Computing; 2020.

- 538 28. fabricatr: Imagine Your Data Before You Collect It. R package version 0.10.0
539 [computer program]. 2019.
- 540 29. Polanin JR and Snilstveit B. Converting between effect sizes. *Campbell*
541 *Systematic Reviews*. 2016;12:1-13.
- 542 30. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC and Muller M.
543 pROC: an open-source package for R and S+ to analyze and compare ROC curves.
544 *BMC Bioinformatics*. 2011;12:77.
- 545 31. PCAmixdata: Multivariate Analysis of Mixed Data. R package version 3.1
546 [computer program]. 2017.
- 547 32. ClassDiscovery: Classes and Methods for "Class Discovery" with Microarrays or
548 Proteomics. R package version 3.3.12. [computer program]. 2019.
- 549 33. Friedman J, Hastie T and Tibshirani R. Regularization Paths for Generalized
550 Linear Models via Coordinate Descent. *J Stat Softw*. 2010;33:1-22.
- 551 34. caret: Classification and Regression Training. R package version 6.0-86.
552 [computer program]. 2020.
- 553 35. boot: Bootstrap R (S-Plus) Functions. R package version 1.3-25. [computer
554 program]. 2020.
- 555 36. Mills PB, Holtz KA, Szefer E, Noonan VK and Kwon BK. Early predictors of
556 developing problematic spasticity following traumatic spinal cord injury: A prospective
557 cohort study. *J Spinal Cord Med*. 2020;43:315-330.
- 558 37. Price DT, McKenney DW, Nalder IA, Hutchinson MF and Kesteven JL. A
559 comparison of two statistical methods for spatial interpolation of Canadian monthly
560 mean climate data. *Agricultural and Forest Meteorology*. 2000;101:81-94.

- 561 38. Willmott CJ. Some Comments on the Evaluation of Model Performance. *Bulletin*
562 *of the American Meteorological Society*. 1982;63:1309-1313.
- 563 39. Hajizadeh S, DeGroot J, TeKoppele JM, Tarkowski A and Collins LV.
564 Extracellular mitochondrial DNA and oxidatively damaged DNA in synovial fluid of
565 patients with rheumatoid arthritis. *Arthritis Res Ther*. 2003;5:R234-40.
- 566 40. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K and
567 Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury.
568 *Nature*. 2010;464:104-7.
- 569 41. Goulopoulou S, McCarthy CG and Webb RC. Toll-like Receptors in the Vascular
570 System: Sensing the Dangers Within. *Pharmacol Rev*. 2016;68:142-67.
- 571 42. Mitchell MD, Peiris HN, Kobayashi M, Koh YQ, Duncombe G, Illanes SE, Rice
572 GE and Salomon C. Placental exosomes in normal and complicated pregnancy. *Am J*
573 *Obstet Gynecol*. 2015;213:S173-81.
- 574 43. Miliotis S, Nicolalde B, Ortega M, Yopez J and Caicedo A. Forms of extracellular
575 mitochondria and their impact in health. *Mitochondrion*. 2019;48:16-30.
- 576 44. Holland O, Dekker Nitert M, Gallo LA, Vejzovic M, Fisher JJ and Perkins AV.
577 Review: Placental mitochondrial function and structure in gestational disorders.
578 *Placenta*. 2017;54:2-9.
- 579 45. Sharp AN, Heazell AE, Crocker IP and Mor G. Placental apoptosis in health and
580 disease. *Am J Reprod Immunol*. 2010;64:159-69.
- 581 46. Heazell AE and Crocker IP. Live and let die - regulation of villous trophoblast
582 apoptosis in normal and abnormal pregnancies. *Placenta*. 2008;29:772-83.

- 583 47. Huppertz B, Kadyrov M and Kingdom JC. Apoptosis and its role in the
584 trophoblast. *Am J Obstet Gynecol.* 2006;195:29-39.
- 585 48. Genbacev O, DiFederico E, McMaster M and Fisher SJ. Invasive cytotrophoblast
586 apoptosis in pre-eclampsia. *Hum Reprod.* 1999;14 Suppl 2:59-66.
- 587 49. Bischoff FZ, Lewis DE and Simpson JL. Cell-free fetal DNA in maternal blood:
588 kinetics, source and structure. *Hum Reprod Update.* 2005;11:59-67.
- 589 50. Kingdom JC, Audette MC, Hobson SR, Windrim RC and Morgen E. A placenta
590 clinic approach to the diagnosis and management of fetal growth restriction. *Am J*
591 *Obstet Gynecol.* 2018;218:S803-S817.
- 592 51. Hafner E, Metzenbauer M, Hofinger D, Stonek F, Schuchter K, Waldhor T and
593 Philipp K. Comparison between three-dimensional placental volume at 12 weeks and
594 uterine artery impedance/notching at 22 weeks in screening for pregnancy-induced
595 hypertension, pre-eclampsia and fetal growth restriction in a low-risk population.
596 *Ultrasound Obstet Gynecol.* 2006;27:652-7.
- 597 52. Costantini D, Walker M, Milligan N, Keating S and Kingdom J. Pathologic basis of
598 improving the screening utility of 2-dimensional placental morphology ultrasound.
599 *Placenta.* 2012;33:845-9.
- 600 53. Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol.*
601 2015;213:S115-22.
- 602 54. Maduray K, Moodley J and Naicker T. Morphometrical analysis of placental
603 functional efficiency in normotensive versus preeclamptic South African black women.
604 *Hypertens Pregnancy.* 2016;35:361-70.

- 605 55. Suri S, Muttukrishna S and Jauniaux E. 2D-Ultrasound and endocrinologic
606 evaluation of placentation in early pregnancy and its relationship to fetal birthweight in
607 normal pregnancies and pre-eclampsia. *Placenta*. 2013;34:745-50.
- 608 56. Burton GJ and Jauniaux E. Pathophysiology of placental-derived fetal growth
609 restriction. *Am J Obstet Gynecol*. 2018;218:S745-S761.
- 610 57. Egbor M, Ansari T, Morris N, Green CJ and Sibbons PD. Morphometric placental
611 villous and vascular abnormalities in early- and late-onset pre-eclampsia with and
612 without fetal growth restriction. *BJOG*. 2006;113:580-9.
- 613 58. Egbor M, Ansari T, Morris N, Green CJ and Sibbons PD. Pre-eclampsia and fetal
614 growth restriction: how morphometrically different is the placenta? *Placenta*.
615 2006;27:727-34.
- 616 59. Vishnyakova PA, Volodina MA, Tarasova NV, Marey MV, Tsvirkun DV, Vavina
617 OV, Khodzhaeva ZS, Kan NE, Menon R, Vysokikh MY and Sukhikh GT. Mitochondrial
618 role in adaptive response to stress conditions in preeclampsia. *Sci Rep*. 2016;6:32410.
- 619 60. Holland OJ, Cuffe JSM, Dekker Nitert M, Callaway L, Kwan Cheung KA,
620 Radenkovic F and Perkins AV. Placental mitochondrial adaptations in preeclampsia
621 associated with progression to term delivery. *Cell Death Dis*. 2018;9:1150.
- 622 61. Teran E, Hernandez I, Tana L, Teran S, Galaviz-Hernandez C, Sosa-Macias M,
623 Molina G and Calle A. Mitochondria and Coenzyme Q10 in the Pathogenesis of
624 Preeclampsia. *Front Physiol*. 2018;9:1561.
- 625 62. Guitart-Mampel M, Juarez-Flores DL, Youssef L, Moren C, Garcia-Otero L,
626 Roca-Agujetas V, Catalan-Garcia M, Gonzalez-Casacuberta I, Tobias E, Milisenda JC,
627 Grau JM, Crispi F, Gratacos E, Cardellach F and Garrabou G. Mitochondrial

- 628 implications in human pregnancies with intrauterine growth restriction and associated
629 cardiac remodelling. *J Cell Mol Med.* 2019;23:3962-3973.
- 630 63. Kalisch-Smith JI, Simmons DG, Dickinson H and Moritz KM. Review: Sexual
631 dimorphism in the formation, function and adaptation of the placenta. *Placenta.*
632 2017;54:10-16.
- 633 64. Broere-Brown ZA, Adank MC, Benschop L, Tielemans M, Muka T, Goncalves R,
634 Bramer WM, Schoufour JD, Voortman T, Steegers EAP, Franco OH and Schalekamp-
635 Timmermans S. Fetal sex and maternal pregnancy outcomes: a systematic review and
636 meta-analysis. *Biol Sex Differ.* 2020;11:26.
- 637 65. Walker MG, Fitzgerald B, Keating S, Ray JG, Windrim R and Kingdom JC. Sex-
638 specific basis of severe placental dysfunction leading to extreme preterm delivery.
639 *Placenta.* 2012;33:568-71.
- 640 66. Muralimanoharan S, Maloyan A and Myatt L. Evidence of sexual dimorphism in
641 the placental function with severe preeclampsia. *Placenta.* 2013;34:1183-9.
- 642 67. Bartsch E, Medcalf KE, Park AL, Ray JG and High Risk of Pre-eclampsia
643 Identification G. Clinical risk factors for pre-eclampsia determined in early pregnancy:
644 systematic review and meta-analysis of large cohort studies. *BMJ.* 2016;353:i1753.
- 645 68. Shen M, Smith GN, Rodger M, White RR, Walker MC and Wen SW. Comparison
646 of risk factors and outcomes of gestational hypertension and pre-eclampsia. *PLoS One.*
647 2017;12:e0175914.
- 648 69. Ershova E, Sergeeva V, Klimenko M, Avetisova K, Klimenko P, Kostyuk E, Veiko
649 N, Veiko R, Izevskaya V, Kutsev S and Kostyuk S. Circulating cell-free DNA
650 concentration and DNase I activity of peripheral blood plasma change in case of

651 pregnancy with intrauterine growth restriction compared to normal pregnancy. *Biomed*

652 *Rep.* 2017;7:319-324.

653 70. Kustanovich A, Schwartz R, Peretz T and Grinshpun A. Life and death of

654 circulating cell-free DNA. *Cancer Biol Ther.* 2019;20:1057-1067.

655

656 **NOVELTY AND SIGNIFICANCE**

657 **1) What Is New**

- 658 • Cell-free circulating mtDNA (CFCmtDNA) concentrations are reduced in plasma
659 from women with preeclampsia at the third trimester.
- 660 • Despite having CFCmtDNA, plasma from women with preeclampsia elicits
661 greater activation of TLR-9.
- 662 • Preeclampsia diagnosis is strongly associated with high circulating
663 concentrations of nDNA, DNase I, and history of preeclampsia, and moderately
664 associated with lower levels of membrane unbound CFCmtDNA, higher maternal
665 BMI, elevated mean arterial pressure, higher maternal age, and higher likelihood
666 of a cesarean section.

667

668 **2) What Is Relevant?**

- 669 • Preeclampsia is associated with placental dysfunction, trophoblast cell death,
670 and oxidative stress, which lead to release of pro-inflammatory factors into the
671 maternal circulation.
- 672 • An increase in the immunostimulatory potency of CFCmtDNA may contribute to
673 the development or establishment of the maternal syndrome in preeclampsia.